Photocoagulation combined with ranibizumab for macular edema secondary to branch retinal vein occlusion

Abstract

Objective To evaluate the clinical efficacy of macular grid photocoagulation combined with intravitreal ranibizumab injection in the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods The data of 50 eyes of 50 patients with macular edema secondary to BRVO from Oct.2013 to Dec.2017 were analyzed retrospectively. All cases were randomly divided into two groups, each group with 25 cases. All cases received intravitreal injection of ranibizumab. The combined group received standard macular grid photocoagulation at 1 week after injection. Results The difference in BCVA and central macular thickness (CMT) were not statistically significant between the two groups before treatment (P>0.05). BCVA was significantly improved and CMT was significantly decreased in both groups at 1, 2 and 6 months after treatment, the differences were statistically significant (P 0.05). Conclusion The single intravitreal injection of ranibizumab or combined with macular grid laser photocoagulation in the treatment of retinal macular edema secondary to BRVO are effective, and the combined effect is more durable. Key words: Macular edema, secondary; Branch, retinal, vein occlusion; Photocoagulation, macular, grid; Ranibizumab